|
2025
|
Invention
|
Dialkyl tryptamines and their therapeutic uses.
The disclosure relates to a compound of formula ... |
|
2024
|
Invention
|
4-hydroxy-n-propyltryptamine. NNNNN-propyltryptamine) is in the form of a monoclinic crystal stru... |
|
|
Invention
|
Crystalline forms of psilacetin.
Crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacet... |
|
|
Invention
|
Crystalline bufotenidine compounds.
The disclosure relates to crystalline form 1 of 5-hydroxy-N,... |
|
|
Invention
|
Crystalline psilacetin derivatives.
The disclosure relates to crystalline psilacetin derivatives... |
|
|
Invention
|
4-ethoxy-n-methyl-n-isopropyltryptamine. The disclosure relates to [2-(4-ethoxy-1H-indol-3-yl)eth... |
|
|
Invention
|
Psilacetin salts. This disclosure relates to crystalline psilacetin salts, to pharmaceutical comp... |
|
|
Invention
|
Crystalline 5-methoxy-dipropyl tryptamine compounds.
The disclosure relates to crystalline form ... |
|
|
Invention
|
5-chlorotryptammonium hydrofumarate. The disclosure relates to 2-(5-chloro-lH-indol-3-yl)ethan-l-... |
|
|
Invention
|
Tryptammonium galactarate. The disclosure relates to bis(2-(1H-indol-3-yl)ethan-1-aminium) (2R, 3... |
|
|
Invention
|
5-methyl-n-isopropyltryptamine. The disclosure relates to N-[2-(5-methyl-lH-indol-3-yl)ethyl]prop... |
|
|
Invention
|
5-methoxy-tryptammonium glutarate. The disclosure relates to bis(2-(5-methoxy-lH-indol-3-yl)ethan... |
|
|
Invention
|
N-ethyltryptamine. NNNN-ethyltryptamine, to compositions containing the same, and to methods of t... |
|
|
Invention
|
5-methyl-n-isopropyltryptammonium hydromaleate. The disclosure relates to [2-(5-methyl-lH-indol-3... |
|
|
Invention
|
N-dicyclopropyltryptammonium chloride. NNNNNNN-dicyclopropyltryptammonium chloride, to compositio... |
|
|
Invention
|
N,n-diisopropyltryptammonium chloride. N,NN,NN,NN,N-diisopropyltryptammonium chloride, to composi... |
|
|
Invention
|
4-methoxy-n-methyl-n-cyclopropyltryptamine. NNNNNNN-cyclopropyltryptamine, to compositions contai... |
|
|
Invention
|
5-methyl-n-isopropyltryptammonium fumarate. The disclosure relates to bis([2-(5-methyl-1H-indol-3... |
|
|
Invention
|
5-methoxytryptammonium hydrophthalate. The disclosure relates to 2-(5-methoxy-1H-indol-3-yl)ethan... |
|
|
Invention
|
4-benzyloxy-n-methyl-n-isopropyltryptammonium chloride. NNNNNNN-isopropyltryptammonium chloride, ... |
|
|
Invention
|
Crystalline bis-miprocin fumarate.
The disclosure relates to crystalline forms of bis(4-hydroxy-... |
|
|
Invention
|
2-(2-ethoxy-4-propylsulfanyl-5 methoxyphenyl)ethanaminium chloride. The disclosure relates to 2-[... |
|
|
Invention
|
Quaternary tryptamines and their therapeutic uses.
The disclosure relates to compounds of formul... |
|
|
Invention
|
Tryptamine derivatives. This disclosure relates to 2-(5-methoxy-1H-indol-3-yl)ethan-1-aminium (2E... |
|
|
Invention
|
Crystalline norpsilocin compounds.
The disclosure relates to norpsilocin compounds, compositions... |
|
|
Invention
|
Compositions and methods comprising a combination of serotonergic drugs.
This disclosure pertain... |
|
|
Invention
|
Tryptamine derivatives. This disclosure relates to trimethyl[2-(2-methyl-lH-indol-3-yl)ethyl]azan... |
|
|
Invention
|
Tryptamine derivatives. This disclosure relates to 2-[4-(benzyloxy)-lH-indol-3-yl]-2-oxo-A/-(prop... |
|
|
Invention
|
2-(2,5-diethoxy-4-(ethylthio)phenyl)ethane-1-aminium chloride. The disclosure relates to 2-[2,5-d... |
|
|
Invention
|
Crystalline 4-hydroxy-n,n-di-n-propyltryptammonium (4-ho-dpt) salts.
This disclosure relates to ... |
|
|
Invention
|
4-hydroxy-n-isopropyltryptamine. The disclosure relates to 3-{2-[(propan-2-yl)amino]ethyl}-1H-ind... |
|
2023
|
Invention
|
Tryptamine derivatives. NNNNNNNNNNN-dimethyl-α-oxo-4-(phenylmethoxy)-1H-indole-3-acetamide, and s... |
|
|
Invention
|
Tryptamine derivatives and their therapeutic uses.
This disclosure relates to tryptamines deriva... |
|
|
Invention
|
Alkyl quaternary ammonium tryptamines and their therapeutic uses.
The disclosure relates to a co... |
|
|
Invention
|
Tryptamine derivatives. This disclosure relates to bis(2-(5-methoxy-1H-indol-3-yl)ethan-1-aminium... |
|
|
Invention
|
Crystalline forms of psilacetin. Crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilaceti... |
|
|
Invention
|
Crystalline n-methyl tryptamine derivatives. NNNNNN,N,NN,N,N-trimethyltryptammonium iodide or TMT... |
|
|
Invention
|
Tryptamine derivatives. N,NN,NN,N-di-n-propyltryptammonium chloride hydrate or 4-[(4-nitrophenyl)... |
|
|
Invention
|
Structure-activity relationships for psilocybin, baeocystin, aeruginascin, and related analogues ... |
|
|
Invention
|
2-(2-ethoxy-4-(ethylthio)-5-methoxyphenyl)ethan-1-aminium chloride.
The disclosure relates to 2-... |
|
|
G/S
|
Pharmaceutical preparations for conditions affecting the serotonergic system; Medical preparation... |
|
|
Invention
|
Methyl substituted quaternary tryptamine derivatives.
This disclosure relates to trimethyl[2-(5-... |
|
|
Invention
|
Crystalline 4-(ethylsulfonyloxy)-n,n-di-n-propyltryptammonium chloride.
This disclosure relates ... |
|
|
Invention
|
Tryptamine derivatives.
This disclosure relates to [2-(5-hydroxy-1H-indol-3-yl)ethyl]tripropylaz... |
|
|
Invention
|
N-isopropyl tryptamines and method of making monoalkylated and dialkylated tryptamine analogs. Th... |
|
|
Invention
|
Crystalline quaternary salts of 4-substituted tryptamines.
The disclosure relates to {2-[4-(acet... |
|
|
Invention
|
Tryptamine derivatives.
The disclosure relates to (2-{4-[(methoxycarbonyl)oxy]-1H-indol-3-yl}eth... |
|
|
Invention
|
Psychedelic compounds and their therapeutic uses.
The disclosure relates to compounds of formula... |
|
2022
|
Invention
|
Psilocybin derivatives. The disclosure relates to forms of 5-[(3-{2-[bis(propan-2-yl)azaniumyl]et... |
|
|
Invention
|
Crystalline tryptamine compounds.
The disclosure relates to 2-(5-hydroxy-1H-indol-3-yl)ethan-1-a... |
|
|
Invention
|
Crystalline hydrochloride salts of substituted tryptamines.
The disclosure relates to substitute... |
